Announcement • Apr 12
Inhalation Sciences Sweden AB (publ) to Report Q1, 2026 Results on May 11, 2026 Inhalation Sciences Sweden AB (publ) announced that they will report Q1, 2026 results on May 11, 2026 Announcement • Jan 29
Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2025 Results on Feb 27, 2026 Inhalation Sciences Sweden AB (publ) announced that they will report fiscal year 2025 results on Feb 27, 2026 Announcement • Oct 23
Inhalation Sciences Sweden AB (publ) to Report Q3, 2025 Results on Nov 21, 2025 Inhalation Sciences Sweden AB (publ) announced that they will report Q3, 2025 results on Nov 21, 2025 Announcement • Oct 08
Inhalation Sciences AB (publ) to Present Abstracts from the FDA-Funded Evaluation Study on Dissolvit and the APRINHA Project at the 2025 DDL Conference Inhalation Sciences AB (ISAB) announced that both of its submitted abstracts have been accepted for presentation at the upcoming Drug Delivery to the Lungs (DDL) Conference in December. ISAB's Chief Scientific Officer and founder, Assoc. Professor. Per Gerde and Director of Projects, PhD Maria Malmlof, will present results from two major research initiatives, highlighting the company's latest advances in inhalation drug development. This recognition underscores ISAB's continued leadership in advancing cutting-edge research within inhaled drug development. Assoc. Professor. PerGerde, will have a podium presentation on the pharmacokinetic (PK) studies from the European research project "New Inhalation Formulations for Improved Delivery of Antimicrobials" (APRINHA). The APRINHA project is developing and evaluating five innovative formulations of the antibiotic apramycin, aiming to create an effective inhaled antibiotic treatment for lower respiratory tract infections (LRTIs), including those caused by antibiotic-resistant bacteria. ISAB was selected to conduct the pharmacokinetic studies in the APRINHA project due to the unique precision and capabilities of its proprietary PreciseInhale®? platform technology. The APRINHA project is coordinated by the University of Zurich and brings together leading academic and industry partners across Europe. Furthermore, PhD Maria Malmlof will present the results from the FDA-funded evaluation study of ISAB's in vitro solution module, DissolvIt®?. This study demonstrates that DissolvIt®? generates pharmacokinetic (PK) data capable of predicting clinical plasma profiles, supporting its use in bioequivalence assessments. In addition to the DDL conference, Inhalation Sciences will also be exhibiting at the upcoming MVIC inhalationposium in Lund on October 8-9, where company representatives will be available at their booth to discuss these studies and broader research into advanced pulmonary drug delivery technologies. Announcement • Jul 30
Inhalation Sciences Sweden AB (publ) to Report First Half, 2025 Results on Aug 29, 2025 Inhalation Sciences Sweden AB (publ) announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • Jun 05
Inhalation Sciences Sweden AB (publ) has completed a Composite Units Offering. Inhalation Sciences Sweden AB (publ) has completed a Composite Units Offering.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 12,000,000
Price\Range: SEK 1
Transaction Features: Rights Offering Announcement • Apr 29
Inhalation Sciences Sweden AB (publ) to Report Q1, 2025 Results on May 28, 2025 Inhalation Sciences Sweden AB (publ) announced that they will report Q1, 2025 results on May 28, 2025 Announcement • Apr 24
Inhalation Sciences AB Reports Positive Primary and Secondary Study Results in the FDA-Funded Study of DissolvIt and Receives Approval from the FDA to Publish the Study Results Inhalation Sciences AB (ISAB) has completed the FDA-funded study of DissolvIt®? (ISAB's proprietary unique methodology for dissolution testing of inhaled drugs) with successful results where all primary and secondary study objectives were confirmed to be met. After final minor amendments, the study report has now been approved by the FDA for publication. The study, which included a total of 16 inhalation products, shows among other things that: DissolvIt®? generates a unique and more detailed set of dissolution data than conventional methods provide, in addition to also reproducing the overall picture of dissolution these methods provide. DissolvIt®? provides equivalent results to more expensive and complex laboratory animal-based methods for measuring lung dissolution such as Isolated Perfused Lung (IPL). DissolvIt®? can detect small differences and rapid time courses in the dissolution profiles of different test formulations, which can be used to develop generic inhalation products in a more targeted manner. The completion of the study with successful results comes at an interesting time as the FDA in late 2024 updated its regulatory guidance with recommendations for inhaled drug development to include dissolution testing as a key component for drug approval. As announced in a separate press release on March 3, 2025, the regulatory updates are expected to lead to an increased use of dissolution and with the positive approved study results from DissolvIt®?, ISAB's position in the growing inhalation drug development market is expected to be strengthened. For drug developers, DissolvIt®?'s ability to generate results in preclinical tests that distinguish the efficacy of different candidates and predict how they will behave in the clinical phase can bring significant benefits by reducing risk, cost, and time in the otherwise complex inhaled drug development process. Announcement • Jan 30
Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025 Inhalation Sciences Sweden AB (publ) announced that they will report fiscal year 2024 results on Feb 28, 2025 Announcement • Jan 09
Inhalation Sciences Sweden AB Submits Project Report and Summary Data to the FDA for Final Review Inhalation Sciences Sweden AB (ISAB) announced the submission of the project report and summary data to the U.S. Food and Drug Administration (FDA) for final review and approval. This marks a key milestone in ISAB's ongoing FDA BAA (Broad Agency Agreement) Contract 75F40122C00197 for a collaborative research project which evaluates the discriminative dissolution potential of its innovative DissolvIt system for assessing drug formulations designed for inhalation therapy. The DissolvIt system is designed to address a critical need in pharmaceutical development: early-stage insights into drug dissolution and absorption in the lungs. These insights can help optimize the development of both new and generic inhalation therapies. Unlike traditional dissolution methods that generate cumulative curves, DissolvIt provides single-pass dissolution data which more closely mimics how the lungs dissolve and absorb drug substances into the stream. This novel capability may support pharmaceutical developers to gain early insights into drug candidates' performance already in pre-clinical stage as well as eliminate non-viable options efficiently. As previously communicated on October 16, 2024, the study evaluated 16 compounds with different formulations, particle sizes, and manufacturing methods, comparing their dissolution and absorption profiles. The results generated indicate that DissolvIt: Can detect similarities and differences in dissolution/absorption profiles with promising accuracy; Has the potential to predict drug concentration levels in clinical plasma profiles; Provides high-resolution data sets valuable for advanced particle-engineered formulations approaching clinical trials. The project - Contract 75F40122C000 - was initially communicated by ISAB on September 15th, 2022. Its completion will represent an important step in demonstrating the value of DissolvIt for advancing inhalation therapy development. Announcement • Oct 22
Inhalation Sciences Sweden AB (publ) to Report Nine Months, 2024 Results on Nov 20, 2024 Inhalation Sciences Sweden AB (publ) announced that they will report nine months, 2024 results on Nov 20, 2024 Announcement • Jul 30
Inhalation Sciences Sweden AB (publ) to Report Q2, 2024 Results on Aug 28, 2024 Inhalation Sciences Sweden AB (publ) announced that they will report Q2, 2024 results on Aug 28, 2024 Announcement • Apr 30
Inhalation Sciences Sweden AB (publ) to Report Q1, 2024 Results on May 28, 2024 Inhalation Sciences Sweden AB (publ) announced that they will report Q1, 2024 results on May 28, 2024 Announcement • Apr 16
Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024 Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024. Announcement • Jan 30
Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024 Inhalation Sciences Sweden AB (publ) announced that they will report fiscal year 2023 results on Feb 28, 2024 Reported Earnings • Nov 24
Third quarter 2023 earnings released: kr0.098 loss per share (vs kr0.31 loss in 3Q 2022) Third quarter 2023 results: kr0.098 loss per share (improved from kr0.31 loss in 3Q 2022). Revenue: kr3.36m (up 89% from 3Q 2022). Net loss: kr1.31m (loss narrowed 63% from 3Q 2022). Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. New Risk • Oct 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (kr71.1m market cap, or US$6.40m). Minor Risks Shareholders have been diluted in the past year (33% increase in shares outstanding). Revenue is less than US$5m (kr15m revenue, or US$1.3m). Announcement • Oct 24
Inhalation Sciences Sweden AB (publ) to Report Q3, 2023 Results on Nov 22, 2023 Inhalation Sciences Sweden AB (publ) announced that they will report Q3, 2023 results on Nov 22, 2023 New Risk • Aug 31
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (kr50.7m market cap, or US$4.62m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr411k net loss next year). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Revenue is less than US$5m (kr15m revenue, or US$1.4m). Announcement • Jul 31
Inhalation Sciences Sweden AB (publ) to Report Q2, 2023 Results on Aug 29, 2023 Inhalation Sciences Sweden AB (publ) announced that they will report Q2, 2023 results on Aug 29, 2023 New Risk • Jul 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (kr43.2m market cap, or US$3.99m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr3.0m net loss next year). Shareholders have been diluted in the past year (33% increase in shares outstanding). Revenue is less than US$5m (kr13m revenue, or US$1.2m). Reported Earnings • Jun 04
First quarter 2023 earnings released: kr0.20 loss per share (vs kr0.30 loss in 1Q 2022) First quarter 2023 results: kr0.20 loss per share (improved from kr0.30 loss in 1Q 2022). Revenue: kr3.24m (up 57% from 1Q 2022). Net loss: kr2.28m (loss narrowed 33% from 1Q 2022). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance. Announcement • May 06
Inhalation Sciences Receives Formal Clearance to Begin the Trial of Inhalation Study Inhalation Sciences Sweden AB (publ) announced that it has now received the formal clearance to begin the experimental phase of the study. The study is now commencing at the company's facilities in Sweden. The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB's Dissolv It technology by comparing drug formulations, aimed for administration via inhalation, with small differences. The project scope also includes in vitro-in vivo correlation (IVIVC) efforts. The proposed work was approved by the FDA Center for Drug Evaluation and Research (CDER). This research project is planned to be finalized by September 2024. Announcement • Jan 30
Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023 Inhalation Sciences Sweden AB (publ) announced that they will report fiscal year 2022 results on Feb 28, 2023 Reported Earnings • Nov 23
Third quarter 2022 earnings released: kr0.31 loss per share (vs kr0.40 loss in 3Q 2021) Third quarter 2022 results: kr0.31 loss per share (improved from kr0.40 loss in 3Q 2021). Revenue: kr1.78m (up 57% from 3Q 2021). Net loss: kr3.51m (loss narrowed 22% from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Jan Hellqvist was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 03
Second quarter 2022 earnings released: kr0.36 loss per share (vs kr0.56 loss in 2Q 2021) Second quarter 2022 results: kr0.36 loss per share (up from kr0.56 loss in 2Q 2021). Revenue: kr4.24m (up 228% from 2Q 2021). Net loss: kr4.06m (loss narrowed 27% from 2Q 2021). Over the next year, revenue is forecast to grow 128%, compared to a 10% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Announcement • Aug 15
Inhalation Sciences Sweden AB (publ) Announces Resignation of Klaus Gottwald from Its Board of Directors Inhalation Sciences Sweden AB's (publ) Board member Klaus Gottwald has announced his intention to leave the Company's Board of Directors. Klaus will remain in his position until a new Board is appointed. Announcement • Aug 05
Inhalation Sciences Receives Landmark FDA Approval for Co-Financing of its Study to Validate Dissolvit as a Standard Research Method in the US The US FDA(Food and Drug Administration) has approved Inhalation Sciences' proposal for a research study aiming to validate the company's in vitro lung simulation model DissolvIt®as an FDA-recommended dissolution technology, and ultimately a new `golden standard' for dissolution testing for inhaled drugs. The FDA will support and co-finance the study with up to 250 000 USD annually for up to two years. The study will commence in the coming months. The US FDA's National Center for Toxicological Research has approved ISAB's research proposal for a study aiming to make ISAB's leading in vitro dissolution testing tool, DissolvIt, a recommended standard research method for inhaled drug development in the US.DissolvIt is recognized as a leading solution in vitro lung data. The study will evaluate DissolvIt's ability to demonstrate in vitro in vivo correlation (IVIVC), as well as bioequivalence, and detect even small formulation differences in a wide range of APIs. Reported Earnings • May 28
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: kr0.30 loss per share (up from kr0.40 loss in 1Q 2021). Revenue: kr2.06m (down 27% from 1Q 2021). Net loss: kr3.40m (loss narrowed 1.4% from 1Q 2021). Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 163%, compared to a 15% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Mårten Winge was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 16
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: kr1.64 loss per share (down from kr1.15 profit in FY 2020). Revenue: kr9.42m (down 7.1% from FY 2020). Net loss: kr16.6m (down 268% from profit in FY 2020). Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 102%, compared to a 24% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year. Announcement • Apr 07
Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022 Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022. Reported Earnings • Mar 05
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: kr1.46 loss per share (down from kr1.15 profit in FY 2020). Revenue: kr9.42m (down 7.1% from FY 2020). Net loss: kr16.6m (down 268% from profit in FY 2020). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 102%, compared to a 24% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 8% per year, which means it is performing significantly worse than earnings. Announcement • Jan 18
Inhalation Sciences Submits Whitepaper to FDA Aiming to Establish DissolvIt® as an FDA-Recommended Standard Research Method in US Inhalation Sciences (ISAB) has submitted a white paper to the US FDA (Food and Drug Administration) aiming to validate its in vitro simulated lung model DissolvIt®as an FDA-recommended technology, and, ultimately, a new standard research method for inhaled drug research in the US. If approved, the FDA will co-fund the project for up to 250 KUSD (approx. 2.2 MSEK) on an annual basis for up to two years. A final decision on approval for the submitted whitepaper is expected in September 2022. Inhalation Sciences has submitted a formal whitepaper to the FDA'sNational Center for Toxicological Research following months of discussions on how DissolvIt® could further improve research and outcomes for inhaled drugs. The research project aims to make DissolvIt®, ISAB's in vitro simulated lung model, FDA-recommended - and ultimately to validate it as a recommended standard research method to be extensively used in inhaled drug development. The FDA's National Center for Toxicological Research funds a range of research projects, prioritizing those that "spur the development of new regulatory approaches that can help improve predictability" and "replace, reduce and/or refine animal testing" (1) .These are all defining characteristic of DissolvIt®, ISAB's advanced simulated lung model that produces simulated in vitro dissolution /absorption data that closely predicts in vivo data, with no animal testing involved. Such in vitro in vivo correlated data (IVIVC data) significantly reduce risk and cost in the early stages of inhaled drug development, as well as improving the safety and precision of inhaled therapies. With papers such as "In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier models" published in the Journal of Aerosol Science(2) in 2021, DissolvIt® has been increasingly recognized as a leading solution in vitro lung data for its ability to mimic the physiology of the lung and generate voluminous clinical-like data. In the DissolvIt® project described in the submitted white paper to FDA, DissolvIt® will be evaluated by matching test formulations against reference formulations using a wide range of substances spanning from fast- to slow-dissolving APIs. The goal is to evaluate the ability of DissolvIt® to detect small formulation differences and evaluate in vitro to in vivo correlation as well as bioequivalence. Announcement • Dec 20
Inhalation Sciences Announces Positive Study Results Inhalation Sciences recently completed clinic study demonstrate that PreciseInhale® hahas reached its clinical objectives. Topline data confirm that ISAB's flagship aerosol generating system PreciseInhale has reached its clinical objectives, with no adverse effects or safety risks, in a recently completed clinical study of 12 subjects that was carried out by CTC (Clinical Trial Consultants), at their research clinic in Uppsala, Sweden. A first aim of the study was to demonstrate that aerosol dosing with PreciseInhale® provides greater precision and control than dosing carried out with a standard commercial inhaler. A second aim was to demonstrate that PreciseInhale® enables "regional targeting"; the targeted exposure with aerosols in a controlled dose to specific regions of the lungs, a much sought-after capability which has not been possible previously in standard aerosol testing. Topline data confirms thatPreciseInhale® has achieved these objectives. Twelve healthy volunteers were enrolled in this study. In the first round of experiments two doses of standard asthma medicine were used: one directly from a standard commercial inhaler and the other one via PreciseInhale®. Results confirm that the accuracy of the dose delivered with PreciseInhale was greater. In a second round of experiments, it was possible to control the dosage to different regions of the lung with PreciseInhale®. Reported Earnings • Aug 30
Second quarter 2021 earnings released: kr0.56 loss per share (vs kr1.92 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: kr1.30m (down 47% from 2Q 2020). Net loss: kr5.59m (down 134% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improved over the past week After last week's 16% share price gain to kr11.00, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 43x in the Life Sciences industry in Sweden. Total returns to shareholders of 22% over the past three years. Announcement • Jun 22
Inhalation Sciences Completes Enrolment in PreciseInhale Clinical Trial Inhalation Sciences Sweden AB (publ) announced that the first 4 healthy volunteer patients were enrolled on Wednesday 16 June. Now all 12 patients have been enrolled onto the study, which is being run by Clinical Trial Consultants AB (CTC), a CRO and clinical trial consultancy with test facilities adjacent to Uppsala University Hospital. Announcement • May 29
Inhalation Sciences Sweden AB (Publ) Receives CTA Approval for Landmark Clinical Trial of Preciseinhale Inhalation Sciences Sweden AB (publ) announced that its Clinical Trial Application to conduct a clinical trial of its aerosol generating system PreciseInhale has been approved by the Swedish Medical Product Agency (Läkemedelsverket). Following approval of the CTA the first healthy volunteers are expected to enter the clinical trial in June this year, with the study planned to be finalized before the end of 2021. Successful clinical validation of PreciseInhale would make it the first aerosol generation platform that could be used from the drug discovery phase, through preclinical in vitro and in vivo studies, all the way to phase I clinical trials in humans. This could significantly reduce translational errors between research stages, accelerating drug development time and reducing risk and costs. Valuation Update With 7 Day Price Move • May 28
Investor sentiment improved over the past week After last week's 18% share price gain to kr10.85, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 40x in the Life Sciences industry in Sweden. Total returns to shareholders of 32% over the past three years. Reported Earnings • May 21
First quarter 2021 earnings released: kr0.40 loss per share (vs kr0.068 profit in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: kr2.84m (down 51% from 1Q 2020). Net loss: kr3.45m (down kr4.04m from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • May 19
Inhalation Sciences AB Provides Revenue Guidance for the Full Year of Fiscal 2021 Inhalation Sciences AB provided revenue guidance for the full year of fiscal 2021. The company sales and sales forecast of approximately SEK 15 million to SEK 20 million for the full year remains, and expect to be able to compensate for the loss in the coming quarters 2021. Is New 90 Day High Low • Feb 25
New 90-day low: kr10.30 The company is down 16% from its price of kr12.20 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 31% over the same period. Announcement • Dec 11
Inhalation Sciences Appoints Paolo Raffaelli as New Chief Commercial Officer to Drive Global Sales Inhalation Sciences (ISAB) has appointed Paolo Raffaelli as its new Chief Commercial Officer (CCO). Mr. Raffaelli has extensive experience driving international sales in a wide range of medical device companies and takes up his position on December 14, 2020. The new CCO will be responsible for driving ISAB sales in Europe, the US and other international markets. He will have overall responsibility for Sales and Marketing activities, with a primary focus on account targeting. Paolo Raffaelli has over 20 years' executive experience in the life science and medical device industry, with extensive sales and marketing management experience, across European and international markets and he has been based in Stockholm, Brussels and the US. Valuation Update With 7 Day Price Move • Nov 23
Market bids up stock over the past week After last week's 22% share price gain to kr12.60, the stock is trading at a trailing P/E ratio of 9.4x, up from the previous P/E ratio of 7.7x. This compares to an average P/E of 40x in the Life Sciences industry in Sweden. Total returns to shareholders over the past three years are 40%. Announcement • Nov 18
Inhalation Sciences Receives New Order Worth EUR 196,000 from University of Vienna The Department of Pharmaceutical Technology and Biopharmaceutics the University of Vienna carrrries out
highly innovative research into new micro and nano formulations of pharmaceuticals. It has now ordered PreciseInhale[®], ISABs high -precision aerosol R&D system, plus its Nose-Only and the unique
Intratracheal Exposure Modules. The total order is worth EUR 196,000. Both of the in vivo modules that the Department ordered employ Precision Dosing - PreciseInhales unique one-animal-at-a-time methodology which
delivers exceptionally precise, competitive lung data from all regions of the lung. With Precision Dosing, researchers can tailor the exact dose from a gentle, highly controllable stream of aerosol, unlike the
conventional high-pressure jet of aerosol used in standard technologies. The intratracheal in vivo module chosen is unique in pre-clinical lung research. It is highly lung-specific, bypassing the animals nasal cavity in a more clinical-like way. The constant monitoring of aerosol concentration and of the animals breathing pattern throughout the
experiment, generates data of world- leading precision, with a typical Standard Deviation of less than 10%. Is New 90 Day High Low • Oct 15
New 90-day low: kr10.80 The company is down 9.0% from its price of kr11.90 on 17 July 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 18% over the same period. Announcement • Oct 05
Inhalation Sciences Announces to Successfully Installed its First Ever Commercial Version of the in Vitro Dissolvit Module at the Swiss Laboratory of a Long-Term ISAB Customer Inhalation Sciences (ISAB) has announced to successfully installed its first ever commercial version of the in vitro DissolvIt module at the Swiss laboratory of a long-term ISAB customer. The module was the first of three shipments that were announced and sent to customers in March just before strict Covid-19 restrictions came into force in many countries worldwide. From its commercial launch in spring 2020, demand for DissolvIt has been strong. Three modules were shipped to three customers in just a couple of weeks following the launch. However, the installations where stalled as Covid-19 lockdown and restrictions on access to laboratories were implemented around the globe. Now, as the restrictions have started to ease up and laboratories are slowly reopening, a team of ISAB representatives has successfully installed the first DissolvIt module at the customer's site in Switzerland. In addition to customers now being able to access DissolvIt at their own laboratories, the disposable sales for each DissolvIt is estimated to €20 000 annually. The in vitro simulation module DissolvIt is seen by many in the inhalation industry as the first tool to show credible, predictive In Vitro-In Vivo Correlated (IVIVC) data. Predictive, preclinical IVIVC data reduces risk, eliminates error and accelerates drug development early on. DissolvIt also achieves 3R goals by reducing, refining, or replacing the number of animals needed for preclinical lung research. DissolvIt delivers: Dissolution and absorption data for ranking of candidate drugs and comparison of generic candidates versus reference drugs · Absorption profiles with C\max\ and T\max\ resembling clinical absorption profiles. Light microscope photos and/or video of real-time dissolution before/during dissolution. 